home > ict > summer 2012 > adapting to change
International Clinical Trials

Adapting to Change

The 11th Annual Partnerships in Clinical Trials Congress and Exhibition focuses on the strategic and practical approaches to improving all partnerships between trial sponsors and their suppliers, in order to reduce costs, improve quality and accelerate clinical development.

The conference, on the 6th-9th November 2012, in the CCH Congress Center, Hamburg, Germany, covers the entire clinical development pipeline for pharmaceuticals and biotech, stretching from outsourced R&D and preclinical through to Phase 3. The key theme for this year’s event is ‘adapting to change: minimising risk through agile development.’ Through lively debate and in-depth discussions, the programme will examine managing risk strategically, with a defined set of criteria for risk-based monitoring. Other key themes include: tactics for efficient operational delivery; critical examination of strategic outsourcing models; and planning and measuring project success.

New additions to the 2012 programme include an expert opinion track, including a panel discussion that will look at the impact of CROs and other vendors going private. There will also be an initiative on outsourcing strategies for small- and medium-pharma and biotech, with a focussed networking opportunity for service providers to meet small- and mediumsized pharma companies.

The economic keynote presentation from Joe Nellis, Professor of International Management Economics, Director of Policy Strategy and Performance Community at Cranfield University will present “a competitive outlook for 2013 and beyond.” His take on leading change through strategic partnerships is simple: “what new businesses, what new alliances, what new partnerships have you not yet thought about which might be the right structures for the future?”

In the industry keynote presentation, John Orloff, Senior Vice President, Global Development and Chief Medical Officer, Novartis Pharma AG, will examine “high level strategic innovations for clinical trials: what needs to change?” This presentation will give an assessment of the current issues and challenges that the industry faces in clinical research.

For inspiration, Didi Hopkins, International Centre for Programme Management, Cranfield School of Management,

and Senior Trainer, The National Theatre, London, will present two workshops at the pre-conference symposium: “gravitas, power and presence – using the language of leadership to improve your public speaking”; and “women in leadership forum: be seen, be heard, be taken seriously.”

Delegates will also have the opportunity to hear from the true leader of the e-patient movement, Dave deBronkart, better known as ‘e-patient Dave’, and learn how this empowered patient beat stage 4 cancer.

The ‘leadership’ keynote comes from Itay Talgam, Music Director of the Tel-Aviv Symphony Orchestra and internationally renowned conductor. Through his humorous and interactive session, ‘lead like the great conductors: getting a brilliant performance without saying a word,’ Itay will examine how to resist micro-management and give space for your partners to perform.

One of the pre-conference workshops will deliver an audience with the FDA, assessing what is expected of risk-based monitoring. This will be presented by Ann Meeker-O’Connell, Acting Associate Director, Risk Science, Intelligence and Prioritization, US Food and Drug Administration, CDER.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.


To learn more about the event visit
To register:, quoting CQ3007EX15

Print this page
Send to a friend
Privacy statement
News and Press Releases

Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022

Stockley Park, UK – 3 November 2022 – Gilead Sciences, Inc. and Kite, a Gilead Company, will support 30 data presentations, including seven oral presentations in large B-cell lymphoma (LBCL) and two oral presentations on investigator-sponsored studies in acute myeloid leukaemia (AML), during the 64th Annual American Society of Hematology (ASH) Annual Meeting (10-13 December).
More info >>

White Papers

Customising the Cold Chain

World Courier

Of all the statistics emerging around the global pharmaceutical industry this year, two big numbers capture the attention of both manufacturers and their logistics partners: $248 billion, the amount the “BRIC” nations (Brazil, Russia, India and China) are poised to account for in pharmaceutical sales for by 2016; and $8 billion, the amount global pharma will spend on cold chain logistics in 2014. Why are these two numbers so noteworthy? They demonstrate that as R&D goes, so goes logistics. As products evolve to meet demands for more targeted therapies, demand for more targeted logistics solutions grows as well. And that means a need for customization for everything from clinical trial samples to finished product.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement